Vivozon Pharmaceutical Balance Sheet Health
Financial Health criteria checks 5/6
Vivozon Pharmaceutical has a total shareholder equity of ₩105.1B and total debt of ₩38.3B, which brings its debt-to-equity ratio to 36.5%. Its total assets and total liabilities are ₩175.7B and ₩70.6B respectively. Vivozon Pharmaceutical's EBIT is ₩4.3B making its interest coverage ratio 2. It has cash and short-term investments of ₩11.8B.
Key information
36.5%
Debt to equity ratio
₩38.32b
Debt
| Interest coverage ratio | 2x |
| Cash | ₩11.85b |
| Equity | ₩105.10b |
| Total liabilities | ₩70.63b |
| Total assets | ₩175.73b |
Recent financial health updates
We Think Vivozon Pharmaceutical (KOSDAQ:082800) Is Taking Some Risk With Its Debt
Dec 02
Vivozon Pharmaceutical (KOSDAQ:082800) Has A Somewhat Strained Balance Sheet
Jul 29We Think Vivozon Pharmaceutical (KOSDAQ:082800) Has A Fair Chunk Of Debt
Mar 23Is Vivozon Healthcare (KOSDAQ:082800) A Risky Investment?
May 06Recent updates
Vivozon Pharmaceutical Co., Ltd.'s (KOSDAQ:082800) Shares Climb 40% But Its Business Is Yet to Catch Up
Dec 12We Think Vivozon Pharmaceutical (KOSDAQ:082800) Is Taking Some Risk With Its Debt
Dec 02Vivozon Pharmaceutical Co., Ltd.'s (KOSDAQ:082800) Shares Climb 35% But Its Business Is Yet to Catch Up
Oct 28What Vivozon Pharmaceutical Co., Ltd.'s (KOSDAQ:082800) 33% Share Price Gain Is Not Telling You
Aug 02Vivozon Pharmaceutical (KOSDAQ:082800) Has A Somewhat Strained Balance Sheet
Jul 29Some Shareholders Feeling Restless Over Vivozon Pharmaceutical Co., Ltd.'s (KOSDAQ:082800) P/S Ratio
Jun 04We Think Vivozon Pharmaceutical (KOSDAQ:082800) Has A Fair Chunk Of Debt
Mar 23Is Vivozon Healthcare (KOSDAQ:082800) A Risky Investment?
May 06Estimating The Intrinsic Value Of Vivozon Healthcare, Inc. (KOSDAQ:082800)
Feb 18Did You Miss Vivozon Healthcare's (KOSDAQ:082800) Impressive 116% Share Price Gain?
Dec 04Financial Position Analysis
Short Term Liabilities: A082800's short term assets (₩42.2B) do not cover its short term liabilities (₩65.6B).
Long Term Liabilities: A082800's short term assets (₩42.2B) exceed its long term liabilities (₩5.0B).
Debt to Equity History and Analysis
Debt Level: A082800's net debt to equity ratio (25.2%) is considered satisfactory.
Reducing Debt: A082800's debt to equity ratio has reduced from 55.9% to 36.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A082800 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: A082800 has sufficient cash runway for 2.8 years if free cash flow continues to grow at historical rates of 12.4% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 12:13 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vivozon Pharmaceutical Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mok Hyun Ji | MERITZ Securities Co., Ltd. |
| Hyun Yong Kim | SK Securities Co., Ltd. |